Suppr超能文献

科学和监管政策委员会关注要点:非临床毒理学研究中临床病理学数据与解剖病理学数据的整合。

Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies.

机构信息

Charles River Laboratories, Inc., Reno, Nevada, USA.

Eli Lilly and Company, Indianapolis, Indiana, USA.

出版信息

Vet Clin Pathol. 2022 Sep;51(3):311-329. doi: 10.1111/vcp.13167. Epub 2022 Aug 17.

Abstract

Integrating clinical pathology data with anatomic pathology data is a common practice when reporting findings in the context of nonclinical toxicity studies and aids in understanding and communicating the nonclinical safety profile of test articles in development. Appropriate pathology data integration requires knowledge of analyte and tissue biology, species differences, methods of specimen acquisition and analysis, study procedures, and an understanding of the potential causes and effects of a variety of pathophysiologic processes. Neglecting these factors can lead to inappropriate data integration or a missed opportunity to enhance understanding and communication of observed changes. In such cases, nonclinical safety information relevant to human safety risk assessment may be misrepresented or misunderstood. This "Points to Consider" manuscript presents general concepts regarding pathology data integration in nonclinical studies, considerations for avoiding potential oversights and errors in data integration, and focused discussion on topics relevant to data integration for several key organ systems, including liver, kidney, and cardiovascular systems.

摘要

将临床病理学数据与解剖病理学数据相结合,是在非临床毒性研究中报告研究结果时的常见做法,有助于理解和交流正在开发的试验品的非临床安全性概况。适当的病理学数据整合需要了解分析物和组织生物学、物种差异、标本采集和分析方法、研究程序,以及对各种病理生理过程的潜在原因和影响的理解。忽视这些因素可能导致数据整合不当或错失增强对观察到的变化的理解和交流的机会。在这种情况下,与人类安全风险评估相关的非临床安全性信息可能会被错误表示或误解。本“要点考虑”文件介绍了非临床研究中病理学数据整合的一般概念,以及避免数据整合中潜在疏忽和错误的注意事项,并重点讨论了与包括肝脏、肾脏和心血管系统在内的几个关键器官系统的数据整合相关的主题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验